171 related articles for article (PubMed ID: 1676210)
21. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy.
McMichael AJ; Griffiths CE; Talwar HS; Finkel LJ; Rafal ES; Hamilton TA; Voorhees JJ
Br J Dermatol; 1996 Jul; 135(1):60-4. PubMed ID: 8776360
[TBL] [Abstract][Full Text] [Related]
22. Corticosteroid-induced cutaneous atrophy and telangiectasia. Experimental production associated with weight loss in rats.
Smith JG; Wehr RF; Chalker DK
Arch Dermatol; 1976 Aug; 112(8):1115-7. PubMed ID: 952530
[TBL] [Abstract][Full Text] [Related]
23. NTP Toxicology and Carcinogenesis Studies of 1,2-Dihydro-2,2,4-Trimethylquinoline (CAS No. 147-47-7) in F344/N Rats and B6C3F1 Mice (Dermal Studies) and the Dermal Initiation/Promotion Study in Female Sencar Mice.
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 Feb; 456():1-312. PubMed ID: 12587020
[TBL] [Abstract][Full Text] [Related]
24. Prospects for future topical glucocorticoid development.
Brattsand R; Särnstrand B
Acta Derm Venereol Suppl (Stockh); 1989; 151():37-46; discussion 47-52. PubMed ID: 2624065
[TBL] [Abstract][Full Text] [Related]
25. [Topical corticosteroids in dermatology--advantages and side effects].
Wojas-Pelc A; Setkowicz M; Bogdaszewska-Czabanowska J
Przegl Lek; 2002; 59(3):170-4. PubMed ID: 12184032
[TBL] [Abstract][Full Text] [Related]
26. The biological properties of Org 6216, a new type of steroid with a selective local anti-inflammatory action.
Fox PK; Lewis AJ; Rae RM; Sim AW; Woods GF
Arzneimittelforschung; 1980; 30(1):55-9. PubMed ID: 7370076
[TBL] [Abstract][Full Text] [Related]
27. Protection from photodamage by topical application of caffeine after ultraviolet irradiation.
Koo SW; Hirakawa S; Fujii S; Kawasumi M; Nghiem P
Br J Dermatol; 2007 May; 156(5):957-64. PubMed ID: 17388926
[TBL] [Abstract][Full Text] [Related]
28. BMY 30047: a novel topically active retinoid with low local and systemic toxicity.
Nair X; Quigley J; Tramposch KM; Carroll FI; Lewin AH; Kiss I
J Pharmacol Exp Ther; 1991 Jan; 256(1):365-70. PubMed ID: 1988666
[TBL] [Abstract][Full Text] [Related]
29. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
30. NTP Toxicology and Carcinogenesis Studies of Diethylphthalate (CAS No. 84-66-2) in F344/N Rats and B6C3F1 Mice (Dermal Studies) with Dermal Initiation/ Promotion Study of Diethylphthalate and Dimethylphthalate (CAS No. 131-11-3) in Male Swiss (CD-1(R)) Mice.
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1995 May; 429():1-286. PubMed ID: 12616302
[TBL] [Abstract][Full Text] [Related]
31. Effect on plasma cortisol level and urinary cortisol excretion, in healthy volunteers, after application of three different topical steroid ointments under occlusion.
Scott M; Malmsten LA; Thelin I
Acta Derm Venereol; 1981; 61(6):543-6. PubMed ID: 6177167
[TBL] [Abstract][Full Text] [Related]
32. Photosensitizing activity of hypericin and hypericin acetate after topical application on normal mouse skin.
Boiy A; Roelandts R; van den Oord J; de Witte PA
Br J Dermatol; 2008 Feb; 158(2):360-9. PubMed ID: 18047507
[TBL] [Abstract][Full Text] [Related]
33. Steroid-induced dermal atrophy. Investigations on discontinuous application.
Lubach D; Bensmann A; Bornemann U
Dermatologica; 1989; 179(2):67-72. PubMed ID: 2529150
[TBL] [Abstract][Full Text] [Related]
34. Topical application of calcipotriene and corticosteroids: combination regimens.
Lebwohl M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S55-8. PubMed ID: 9344186
[TBL] [Abstract][Full Text] [Related]
35. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.
Gans EH; Sadiq I; Stoudemayer T; Stoudemayer M; Kligman AM
J Drugs Dermatol; 2008 Jan; 7(1):28-32. PubMed ID: 18246695
[TBL] [Abstract][Full Text] [Related]
36. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects.
Thalén A; Brattsand R; Andersson PH
Acta Derm Venereol Suppl (Stockh); 1989; 151():11-9; discussion 47-52. PubMed ID: 2624062
[TBL] [Abstract][Full Text] [Related]
37. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
Meyer E; Smith EW; Haigh JM; Kanfer I
Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and pharmacological evaluation of new topical anti-inflammatory steroids.
Sin KS; Lee HJ; Kim HP
Drugs Exp Clin Res; 1991; 17(8):375-80. PubMed ID: 1822829
[TBL] [Abstract][Full Text] [Related]
39. [Toxicological examination of pure diflucortolone valerate and its formulations as ointment, fatty ointment and cream in animal experiments (author's transl)].
Günzel VP; Etreby MF; Bhargava AS; Poggel HA; Schöbel C; Schuppler J; Siegmund F; Staben P
Arzneimittelforschung; 1976; 26(7b):1476-9. PubMed ID: 1036942
[TBL] [Abstract][Full Text] [Related]
40. Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: in vitro comparison on HaCaT.
Guichard A; Humbert P; Tissot M; Muret P; Courderot-Masuyer C; Viennet C
Int J Pharm; 2015 Feb; 479(2):422-9. PubMed ID: 25556056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
